News Release

Smokers with heart disease could gain five healthy years by quitting

Reports and Proceedings

European Society of Cardiology

Sophia Antipolis – 7 April 2022:  Smoking cessation adds the same number of heart disease-free years to life as three preventive medications combined, according to research presented at ESC Preventive Cardiology 2022, a scientific congress of the European Society of Cardiology (ESC).1

“The benefits of smoking cessation are even greater than we realised,” said study author Dr. Tinka Van Trier of Amsterdam University Medical Centre, the Netherlands. “Our study shows that kicking the habit appears to be as effective as taking three medications for preventing heart attacks and strokes in those with a prior heart attack or procedure to open blocked arteries. Patients could gain nearly five years of healthy life.”

“This analysis focused on smokers who had experienced a heart attack and/or undergone stent implantation or bypass surgery,” she added. “This group is at particularly high risk of having another heart attack or a stroke and stopping smoking is potentially the most effective preventive action.”

The study used data from 989 patients aged 45 years and older who were still smoking at least six months after having a heart attack and/or undergoing stent implantation or bypass surgery. The average age was 60 years and 23% were women. Patients were generally well treated with standard preventive medications (antiplatelets, statins and blood pressure-lowering drugs). The median time since the heart attack or procedure was 1.2 years.

The researchers used the SMART-REACH model (available at to estimate the gain in healthy years, i.e. without a heart attack or stroke, if patients quit smoking. They also calculated the gain in healthy years if patients continued smoking but took three additional drugs to prevent cardiovascular disease. The three medications included bempedoic acid and PCSK9 inhibitors, which lower LDL (“bad”) cholesterol, and colchicine, an anti-inflammatory therapy. 

The researchers found that the estimated benefit of quitting smoking appeared to be comparable to using all three pharmaceutical treatments. Smoking cessation resulted in a gain of 4.81 event-free years while the three medications together provided a gain of 4.83 event-free years.

“This indicates that smoking cessation is a very important step towards adding healthy years to one’s lifetime,” said Dr. Van Trier. “It is important to remember that the analysis did not even account for the other advantages of giving up the habit – for example on respiratory illnesses, cancer and longevity.”

She continued: “Smoking cessation remains a cornerstone of preventing heart attacks and strokes and improving overall health at any time, including after a heart attack and at any age. We know that cigarette smoking is responsible for 50% of all avoidable deaths in smokers, of which half are due to cardiovascular disease.2 Giving up cigarettes after a heart attack is linked with improved survival compared with persistent smoking.3

Dr. Van Trier concluded: “If you are considering becoming smokefree, or would like more information about it, please talk to a health professional. Your motivation is key to successfully quitting, but beating an addiction becomes easier with medical and psychological assistance.”



Authors: ESC Press Office

Mobile: +33 (0)7 8531 2036

Follow us on Twitter @ESCardioNews 


Funding: None.


Disclosures: None.


References and notes

1The abstract ‘Overall benefits of smoking cessation in patients with ASCVD are underestimated’ will be presented during ‘Moderated posters session 1 - Secondary Prevention and Rehabilitation’ which takes place on 7 April at 17:05 CEST.

2Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227–3337.

3Gerber Y, Rosen LJ, Goldbourt U, et al. Smoking status and long-term survival after first acute myocardial infarction a population-based cohort study. J Am Coll Cardiol. 2009;54:2382–2387.


About the European Association of Preventive Cardiology

The European Association of Preventive Cardiology (EAPC) is a branch of the ESC. Its mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.


About ESC Preventive Cardiology 2022  #ESCPrev2022

ESC Preventive Cardiology 2022, formerly EuroPrevent, is the leading international congress on preventive cardiology and the annual congress of the European Association of Preventive Cardiology (EAPC) of the European Society of Cardiology (ESC).

About the European Society of Cardiology

The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.


Information for journalists about registration for ESC Preventive Cardiology 2022

ESC Preventive Cardiology 2022 takes place 7 to 9 April online. Explore the scientific programme.

  • Credentials: A valid press card or appropriate letter of assignment with proof of three recent published articles (cardiology or health-related or referring to a previous ESC event). Read the ESC media and embargo policy.
  • The ESC Press Office will verify the documents and confirm by email that your press accreditation is valid.
  • The ESC Press Office decision is final regarding all press registration requests.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.